Cody Moore
Director - Platform Development iBio
Cody Moore is Director of Platform Development at iBio, where he leads platform R&D efforts supporting the discovery and development of next-generation biologics. He joined iBio in 2022 as Senior Manager, Platform R&D, following more than four years at RubrYc Therapeutics, where he progressed from Scientist I to Platform R&D Manager. Earlier in his career, he worked as a Scientist at HealthTell. His experience spans platform development, biologics research and the advancement of innovative therapeutic discovery technologies.
Seminars
Wednesday 2nd December 2026
Decoding Amylin Receptor Specificity to Engineer a More Precise, Long Acting Therapeutic
1:30 pm
- Explore how fully selective antibodies can distinguish between AMY1, AMY3 and calcitonin receptor activity, moving beyond broadly biased peptide agonists to identify which receptor profiles drive weight loss, tolerability and body-composition outcomes
- Examine how parallel interrogation of G-protein and β-arrestin signaling can connect cellular mechanism with in vivo performance, enabling more rational optimization of potency, signaling bias and receptor engagement rather than relying on clinical trialand-error
- Assess the potential of ultra-long-acting amylin antibodies to deliver infrequent dosing, sustained receptor coverage and improved treatment adherence, helping developers pursue durable efficacy while reducing adverse effects, treatment burden and weight cycling
